Evidence map›Paper›PMID 40091615›Full record

ArticleAnnals of medicine2025

The addition of alpha-ketoglutarate to NT-proBNP improves the prediction of long-term all-cause mortality in acute heart failure patients.

Tianyu Xu, Hao Zhang, Zhengliang Peng, Yuli Huang, Qiong Zhan, Zhuang Ma, Xianghui Zeng, Chen Liu, Qingchun Zeng, Yugang Dong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tianyu XuNHC Key Laboratory of Assisted Circulation and Vascular Diseases, Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Hao ZhangState Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhengliang PengDepartment of Emergency, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Yuli HuangDepartment of Cardiology, Shunde Hospital, Southern Medical University (the First People's Hospital of Shunde), Foshan, China.ORCID 0000-0001-5423-5487
Qiong ZhanState Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhuang MaState Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xianghui ZengState Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chen LiuNHC Key Laboratory of Assisted Circulation and Vascular Diseases, Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qingchun ZengState Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yugang DongNHC Key Laboratory of Assisted Circulation and Vascular Diseases, Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Dingli XuState Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAlpha-ketoglutarate (AKG), is a major intermediate metabolite of the tricarboxylic acid cycle, and is closely associated with cardiometabolic disease prognosis. Previous studies indicated that AKG is related to myocardial energy expenditure levels and reflects adverse short-term outcomes in heart failure (HF) patients. In this prospective cohort study, we examined the long-term prognostic value of AKG levels in acute HF (AHF) patients.

methodsPlasma AKG levels were assessed in patients hospitalized with AHF. Hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality were calculated via multiple Cox regression. All-cause mortality was compared between patients with NT-proBNP < 1000 pg/ml and those with NT-proBNP ≥ 1000 pg/ml via subgroup analysis.

resultsPatients with AKG ≥ 9.83 μg/ml had higher heart rates and NT-proBNP and lower left ventricular ejection fraction (LVEF) and systolic blood pressure (SBP). After multiple adjustment, higher AKG was associated with an increased all-cause mortality risk (HR = 1.078, p < 0.001). Compared with AKG < 9.83 μg/ml, AKG ≥ 9.83 μg/ml nearly doubled (HR = 1.929, p < 0.001) and quadrupled (HR = 4.160, CONCLUSIONS AND RELEVANCE: Plasma AKG was independently associated with greater all-cause mortality risk in patients with AHF. Higher AKG levels retained prognostic value for patients with relatively low NT-proBNP.

Indexed as

Heart FailureKetoglutaric AcidsNatriuretic Peptide, BrainPeptide FragmentsAcute DiseaseAgedAged, 80 and overBiomarkersCause of DeathFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsBiomarkersKetoglutaric AcidsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Alpha-ketoglutarateheart failurelong-term all-cause mortalityNT-proBNPprognosis

Identifiers

PMID40091615
PMCPMC11915736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.